▁Introduction 7.8203125
: 1.90625
<0x0A> 6.52734375
M 4.66796875
el 4.48828125
an 2.740234375
oma 0.340087890625
, 2.58984375
▁a 1.794921875
▁form 2.71484375
▁of 0.0028533935546875
▁skin 0.2232666015625
▁cancer 0.0053253173828125
, 0.12493896484375
▁has 2.6953125
▁experienced 5.9140625
▁significant 3.111328125
▁adv 2.474609375
anc 1.9541015625
ements 7.045269012451172e-05
▁in 0.1771240234375
▁treat 4.44921875
ments 0.0033092498779296875
▁in 1.826171875
▁recent 0.48291015625
▁years 0.11126708984375
. 0.456787109375
▁Among 5.08203125
▁these 0.6591796875
▁adv 0.900390625
anc 0.06866455078125
ements 1.0609626770019531e-05
, 1.4990234375
▁imm 1.7041015625
une 1.890625
▁check 0.1666259765625
point 0.006992340087890625
▁in 0.192626953125
hib 0.00011420249938964844
itors 0.0906982421875
▁and 3.9296875
▁adj 4.91015625
uv 0.01503753662109375
ant 0.044525146484375
▁ther 0.6318359375
ap 1.1689453125
ies 0.00023865699768066406
▁have 0.537109375
▁emer 1.4912109375
ged 0.00017535686492919922
▁as 0.0428466796875
▁prom 1.1396484375
ising 0.00017261505126953125
▁approaches 2.806640625
. 2.423828125
▁This 2.666015625
▁ess 4.2890625
ay 0.000423431396484375
▁expl 3.193359375
ores 0.00554656982421875
▁the 0.223876953125
▁potential 2.134765625
▁benefits 1.8193359375
▁of 0.499755859375
▁these 1.181640625
▁treat 1.1064453125
ments 3.540515899658203e-05
, 1.4765625
▁their 2.353515625
▁imp 3.701171875
lications 0.0049896240234375
▁for 0.14453125
▁patients 1.7958984375
▁at 7.00390625
▁different 2.99609375
▁stages 0.08074951171875
▁of 0.059417724609375
▁mel 0.65185546875
an 5.447864532470703e-05
oma 0.0006079673767089844
, 0.267578125
▁and 0.04083251953125
▁their 2.119140625
▁impact 1.7529296875
▁on 0.0122833251953125
▁impro 5.71484375
ving 7.343292236328125e-05
▁surv 1.6494140625
ival 0.01532745361328125
▁rates 0.1805419921875
. 0.39208984375
▁Furthermore 4.2734375
, 0.001300811767578125
▁it 0.59912109375
▁will 2.498046875
▁draw 7.02734375
▁on 1.177734375
▁research 3.083984375
▁evidence 2.15234375
▁and 1.8720703125
▁analyze 5.95703125
▁the 1.3623046875
▁case 6.02734375
▁of 0.59228515625
▁Mr 4.296875
. 0.04364013671875
▁B 4.1171875
▁as 4.64453125
▁an 0.5595703125
▁illustr 1.849609375
ative 0.89892578125
▁example 0.038177490234375
. 1.4892578125
<0x0A> 0.306884765625
Body 7.9453125
: 0.307373046875
<0x0A> 1.833984375
I 4.3515625
. 0.0626220703125
▁Im 3.076171875
m 0.318115234375
une 0.005100250244140625
▁Check 0.951171875
point 0.0176544189453125
▁In 0.01407623291015625
hib 2.4437904357910156e-05
itors 0.0140838623046875
: 0.56591796875
<0x0A> 0.2105712890625
A 1.38671875
. 0.045074462890625
▁Mechan 3.607421875
ism 0.045379638671875
▁of 0.2529296875
▁Action 0.0601806640625
: 0.07098388671875
<0x0A> 0.17822265625
Im 0.345947265625
m 0.00673675537109375
une 0.0002605915069580078
▁check 0.014801025390625
point 0.00508880615234375
▁in 0.0018329620361328125
hib 5.9604644775390625e-06
itors 0.0024089813232421875
, 3.58203125
▁such 0.68701171875
▁as 0.0003135204315185547
▁p 2.11328125
emb 0.0031604766845703125
rol 0.00042939186096191406
iz 0.000518798828125
um 0.0005383491516113281
ab 0.00015473365783691406
▁and 0.82861328125
▁n 0.32666015625
iv 0.0003273487091064453
ol 0.0009336471557617188
um 0.0008878707885742188
ab 8.463859558105469e-05
, 0.013580322265625
▁aim 5.25
▁to 0.007488250732421875
▁enh 2.712890625
ance 2.002716064453125e-05
▁the 0.2232666015625
▁body 1.083984375
' 1.0556640625
s 0.00012683868408203125
▁imm 0.2242431640625
une 0.002841949462890625
▁response 0.364990234375
▁against 0.984375
▁mel 1.45703125
an 1.7762184143066406e-05
oma 0.0019502639770507812
▁cells 1.2509765625
▁by 0.759765625
▁blocking 0.49365234375
▁the 0.974609375
▁suppress 8.296875
ive 0.055328369140625
▁signals 2.24609375
▁im 7.55859375
posed 0.4443359375
▁by 0.08135986328125
▁specific 4.12890625
▁imm 1.470703125
une 0.0172882080078125
▁check 0.18359375
points 0.3447265625
, 2.666015625
▁like 3.7578125
▁P 0.6142578125
D 0.005626678466796875
- 0.033416748046875
1 0.02008056640625
/ 1.615234375
PD 0.047943115234375
- 0.006366729736328125
L 0.00457000732421875
1 0.00263214111328125
▁and 2.037109375
▁CT 0.0296478271484375
LA 0.00015056133270263672
- 0.10791015625
4 0.00235748291015625
. 1.248046875
<0x0A> 1.728515625
B 0.361083984375
. 0.0013742446899414062
▁Effect 4.875
iveness 0.1473388671875
▁and 2.830078125
▁Long 6.1640625
- 0.010345458984375
term 1.1103515625
▁Rem 4.30078125
ission 0.076416015625
: 0.26318359375
<0x0A> 0.0080108642578125
Res 2.734375
earch 0.00067138671875
▁has 1.0224609375
▁shown 0.64794921875
▁substantial 8.75
▁promise 3.677734375
▁in 0.802734375
▁imm 3.333984375
une 0.0494384765625
▁check 0.00743865966796875
point 0.00774383544921875
▁in 0.01496124267578125
hib 1.2755393981933594e-05
itors 0.055816650390625
, 1.3701171875
▁leading 3.94921875
▁to 0.0216827392578125
▁impress 4.03125
ive 0.001102447509765625
▁response 3.46484375
▁rates 0.021240234375
▁and 0.703125
▁dur 2.11328125
able 0.051300048828125
, 5.51171875
▁long 0.127197265625
- 0.002193450927734375
term 0.08843994140625
▁rem 0.057861328125
ission 0.4130859375
▁in 0.5654296875
▁patients 1.2734375
▁with 0.1064453125
▁advanced 0.21142578125
▁mel 0.332275390625
an 4.2319297790527344e-05
oma 0.0028743743896484375
. 0.300048828125
▁C 5.07421875
lin 0.1224365234375
ical 0.0043182373046875
▁tri 0.1568603515625
als 1.430511474609375e-05
▁demonstrated 4.54296875
▁a 1.892578125
▁significant 2.962890625
▁surv 3.560546875
ival 0.00013315677642822266
▁advantage 1.8486328125
▁for 1.1318359375
▁patients 0.47900390625
▁treated 0.7705078125
▁with 0.0022373199462890625
▁p 1.8427734375
emb 0.004100799560546875
rol 9.250640869140625e-05
iz 0.00011217594146728516
um 0.00031113624572753906
ab 6.306171417236328e-05
▁and 2.416015625
▁n 0.0662841796875
iv 0.00015044212341308594
ol 0.0004589557647705078
um 0.00012242794036865234
ab 0.0001888275146484375
▁compared 0.463623046875
▁to 0.0643310546875
▁traditional 3.296875
▁ther 1.123046875
ap 0.034698486328125
ies 2.384185791015625e-06
. 0.80517578125
<0x0A> 0.3583984375
C 1.1513671875
. 0.001232147216796875
▁Imp 2.267578125
lications 0.1712646484375
▁for 0.06817626953125
▁Pat 0.49951171875
ients 0.03265380859375
▁at 0.845703125
▁D 0.08599853515625
ifferent 0.0009140968322753906
▁St 0.0102691650390625
ages 2.300739288330078e-05
: 1.0791015625
<0x0A> 0.005168914794921875
1 6.4296875
. 0.03497314453125
▁Advanced 2.306640625
▁Mel 0.96337890625
an 2.849102020263672e-05
oma 0.0017099380493164062
: 0.1365966796875
▁Im 2.595703125
m 0.09912109375
une 0.0006952285766601562
▁check 0.007076263427734375
point 0.0023860931396484375
▁in 0.0022335052490234375
hib 3.933906555175781e-06
itors 0.004062652587890625
▁have 0.912109375
▁proven 2.767578125
▁particularly 3.51953125
▁effective 0.250244140625
▁in 0.347900390625
▁patients 1.25390625
▁with 0.023712158203125
▁advanced 0.06268310546875
▁or 3.62890625
▁met 0.196533203125
ast 5.626678466796875e-05
atic 0.004962921142578125
▁mel 0.0498046875
an 1.8477439880371094e-05
oma 0.00103759765625
, 0.5498046875
▁ach 3.8984375
ieving 3.3736228942871094e-05
▁higher 3.361328125
▁response 0.132568359375
▁rates 0.0293121337890625
▁and 0.30224609375
▁superior 5.22265625
▁overall 1.3271484375
▁surv 0.0125579833984375
ival 0.00016689300537109375
▁compared 0.371826171875
▁to 0.01163482666015625
▁standard 2.833984375
▁treat 1.6044921875
ments 1.621246337890625e-05
. 0.14599609375
<0x0A> 0.317138671875
2 0.02020263671875
. 0.0004696846008300781
▁Early 0.69384765625
- 0.419677734375
stage 0.426513671875
▁Mel 0.0816650390625
an 4.553794860839844e-05
oma 0.0006861686706542969
: 0.00926971435546875
▁Studies 4.39453125
▁are 1.8818359375
▁under 1.533203125
way 0.0017004013061523438
▁to 0.06573486328125
▁investigate 2.65234375
▁the 0.08984375
▁potential 0.68994140625
▁role 2.470703125
▁of 0.004146575927734375
▁imm 0.059051513671875
une 0.006084442138671875
▁check 0.0013990402221679688
point 0.0037403106689453125
▁in 0.003582000732421875
hib 5.960464477539062e-07
itors 0.00479888916015625
▁in 0.129638671875
▁adj 4.6796875
uv 0.0016498565673828125
ant 0.0001621246337890625
▁ther 0.248291015625
apy 0.0850830078125
▁settings 6.5546875
, 0.8046875
▁which 2.73828125
▁may 1.2001953125
▁improve 2.2734375
▁out 1.533203125
comes 0.00012254714965820312
▁and 2.623046875
▁reduce 0.5341796875
▁rec 1.8984375
urrence 0.1387939453125
▁rates 0.4794921875
▁in 0.859375
▁patients 0.51025390625
▁with 0.125244140625
▁earlier 3.037109375
▁stages 1.076171875
▁of 0.039825439453125
▁mel 0.2919921875
an 3.135204315185547e-05
oma 0.00024509429931640625
. 0.029296875
<0x0A> 0.02392578125
II 0.345947265625
. 0.0024356842041015625
▁Ad 0.01248931884765625
j 0.00042128562927246094
uv 0.00021767616271972656
ant 0.00022351741790771484
▁Ther 0.01525115966796875
ap 0.42333984375
ies 7.271766662597656e-06
: 0.0137786865234375
<0x0A> 0.00860595703125
A 0.11395263671875
. 0.00122833251953125
▁Com 5.4375
bin 0.14453125
ation 0.14111328125
▁Ther 0.6083984375
ap 0.8798828125
ies 6.9141387939453125e-06
: 0.08721923828125
<0x0A> 0.04266357421875
Com 1.576171875
bin 0.00563812255859375
ations 4.515625
▁of 0.045196533203125
▁imm 0.52880859375
une 0.2529296875
▁check 0.0159454345703125
point 0.00432586669921875
▁in 0.005992889404296875
hib 7.152557373046875e-07
itors 0.00394439697265625
▁with 0.82177734375
▁other 0.438720703125
▁adj 4.078125
uv 0.002132415771484375
ant 0.020965576171875
▁ther 0.213623046875
ap 0.0030155181884765625
ies 3.814697265625e-06
, 0.24560546875
▁such 0.18701171875
▁as 0.0002002716064453125
▁target 1.25390625
ed 0.0024509429931640625
▁ther 0.1553955078125
ap 0.210205078125
ies 6.4373016357421875e-06
▁or 1.0703125
▁radi 3.73828125
other 0.0007429122924804688
apy 0.01293182373046875
, 0.005340576171875
▁show 4.76171875
▁potential 2.037109375
▁in 2.29296875
▁impro 0.67578125
ving 7.510185241699219e-06
▁treatment 2.748046875
▁out 0.3212890625
comes 5.1021575927734375e-05
▁and 1.484375
▁prevent 4.078125
ing 0.01425933837890625
▁tum 4.41015625
or 0.033233642578125
▁re 2.775390625
lapse 0.1031494140625
. 0.1754150390625
<0x0A> 0.138427734375
B 0.030731201171875
. 0.0003650188446044922
▁Effect 4.75
iveness 0.2274169921875
▁in 1.5986328125
▁Red 2.09375
uc 0.00589752197265625
ing 2.6226043701171875e-06
▁Rec 0.26953125
urrence 0.03839111328125
: 0.5986328125
<0x0A> 0.0228729248046875
C 3.337890625
lin 0.0106048583984375
ical 0.0002956390380859375
▁tri 0.10357666015625
als 1.430511474609375e-06
▁have 0.399169921875
▁illustrated 6.66015625
▁the 0.572265625
▁effect 1.0400390625
iveness 0.0012826919555664062
▁of 0.004405975341796875
▁adj 0.21826171875
uv 0.0017147064208984375
ant 0.00013625621795654297
▁ther 0.33203125
ap 0.18505859375
ies 9.5367431640625e-07
▁in 0.302001953125
▁significantly 5.890625
▁reducing 0.04730224609375
▁the 0.4404296875
▁risk 0.12451171875
▁of 0.0019025802612304688
▁rec 0.8603515625
urrence 0.022491455078125
▁in 1.12109375
▁patients 0.11334228515625
▁with 0.056732177734375
▁high 1.7822265625
- 0.01274871826171875
ris 0.0009288787841796875
k 5.9604644775390625e-06
▁mel 0.293212890625
an 1.2874603271484375e-05
omas 5.0390625
▁after 4.1875
▁surg 0.265380859375
ical 1.0341796875
▁removal 1.13671875
. 0.919921875
<0x0A> 0.405029296875
C 0.1676025390625
. 0.0005478858947753906
▁Imp 0.469482421875
lications 0.0162200927734375
▁for 0.01800537109375
▁Pat 0.313720703125
ients 0.0275726318359375
▁at 0.78564453125
▁D 0.1885986328125
ifferent 0.0019254684448242188
▁St 0.0097503662109375
ages 7.152557373046875e-06
: 0.039154052734375
<0x0A> 0.0087738037109375
1 0.18017578125
. 0.0009031295776367188
▁Inter 6.21875
mediate 0.020263671875
▁to 5.0625
▁High 0.114501953125
- 0.1790771484375
ris 0.323974609375
k 7.95125961303711e-05
▁Mel 0.316650390625
an 0.00026297569274902344
oma 0.339599609375
: 0.035888671875
▁Ad 0.7197265625
j 0.001232147216796875
uv 0.0011920928955078125
ant 0.0003097057342529297
▁ther 0.08087158203125
ap 0.1512451171875
ies 4.76837158203125e-07
▁have 2.091796875
▁shown 1.9736328125
▁prom 1.681640625
ising 0.00014913082122802734
▁results 0.21728515625
▁in 0.050018310546875
▁impro 2.306640625
ving 1.430511474609375e-05
▁surv 1.5498046875
ival 0.0019073486328125
▁rates 0.61279296875
▁and 0.396728515625
▁prolong 5.5625
ing 0.007579803466796875
▁rem 1.90625
ission 0.04449462890625
▁in 0.4619140625
▁patients 0.1585693359375
▁at 4.20703125
▁intermediate 0.8740234375
▁to 0.267822265625
▁high 0.002521514892578125
- 0.73193359375
ris 0.000446319580078125
k 0.0002582073211669922
▁stages 2.548828125
▁of 0.319091796875
▁mel 0.023223876953125
an 6.16312026977539e-05
oma 0.0007491111755371094
, 1.7724609375
▁reducing 2.720703125
▁the 0.140869140625
▁ch 4.8515625
ances 4.5418739318847656e-05
▁of 0.0035858154296875
▁rec 0.86572265625
urrence 0.0212860107421875
▁and 1.0029296875
▁disease 3.806640625
▁pro 0.0555419921875
gression 0.0005488395690917969
. 0.047393798828125
<0x0A> 0.006565093994140625
2 0.0657958984375
. 0.0004489421844482422
▁Low 1.611328125
- 0.010406494140625
ris 0.0227203369140625
k 4.374980926513672e-05
▁Mel 0.0243377685546875
an 5.4836273193359375e-05
oma 0.006740570068359375
: 0.0062408447265625
▁The 3.333984375
▁role 0.861328125
▁of 0.006168365478515625
▁adj 0.0098114013671875
uv 0.001682281494140625
ant 0.000507354736328125
▁ther 0.0108642578125
ap 0.1490478515625
ies 2.7894973754882812e-05
▁in 0.1429443359375
▁low 0.8310546875
- 0.0029754638671875
ris 0.0006618499755859375
k 3.0159950256347656e-05
▁mel 0.158203125
an 0.00015485286712646484
oma 0.3017578125
▁is 0.7216796875
▁not 3.306640625
▁yet 0.9130859375
▁well 1.12109375
- 0.86767578125
est 0.228515625
ab 1.430511474609375e-05
lished 1.4066696166992188e-05
. 1.6318359375
▁More 2.53125
▁research 0.2152099609375
▁is 0.0458984375
▁needed 0.14794921875
▁to 0.012725830078125
▁determine 0.6845703125
▁their 1.4140625
▁potential 1.2900390625
▁benefits 0.6376953125
▁in 0.8740234375
▁this 0.307373046875
▁patient 1.97265625
▁population 0.3125
. 0.029388427734375
<0x0A> 0.0116424560546875
III 1.16796875
. 0.0013828277587890625
▁Imp 2.13671875
lications 0.3837890625
▁for 0.1824951171875
▁Sur 1.14453125
v 0.00579833984375
ival 4.208087921142578e-05
▁R 0.0673828125
ates 0.00585174560546875
▁and 2.826171875
▁Mr 7.12109375
. 0.006221771240234375
▁B 0.00473785400390625
' 0.300537109375
s 0.0006537437438964844
▁Case 0.1053466796875
: 0.05133056640625
<0x0A> 0.0033016204833984375
A 0.33740234375
. 0.0019474029541015625
▁Imp 2.6953125
act 1.3193359375
▁on 0.10504150390625
▁Sur 0.1331787109375
v 0.0006451606750488281
ival 1.1920928955078125e-05
▁R 0.025482177734375
ates 0.00084686279296875
: 0.0300750732421875
<0x0A> 0.029296875
The 1.568359375
▁introduction 2.798828125
▁of 0.0124969482421875
▁imm 0.10906982421875
une 0.006198883056640625
▁check 0.0011806488037109375
point 0.0019292831420898438
▁in 0.0008554458618164062
hib 3.5762786865234375e-07
itors 0.0016889572143554688
▁and 0.01433563232421875
▁adj 0.015594482421875
uv 0.00016868114471435547
ant 0.0003962516784667969
▁ther 0.0069122314453125
ap 0.0016803741455078125
ies 2.384185791015625e-07
▁has 0.2242431640625
▁significantly 0.87109375
▁en 4.09765625
hanced 0.0006833076477050781
▁surv 0.99267578125
ival 0.0006628036499023438
▁rates 0.0228424072265625
▁in 1.30078125
▁patients 0.2030029296875
▁with 0.00940704345703125
▁advanced 1.9423828125
▁mel 1.3017578125
an 9.655952453613281e-06
oma 0.0015115737915039062
. 0.76708984375
▁These 2.220703125
▁treat 0.384521484375
ments 9.059906005859375e-06
▁offer 2.875
▁new 1.7822265625
▁hope 0.20849609375
▁for 0.400390625
▁long 5.7421875
- 0.0014390945434570312
term 0.0220794677734375
▁rem 0.1304931640625
ission 0.01184844970703125
. 5.40234375
<0x0A> 0.0491943359375
B 0.02923583984375
. 0.0003685951232910156
▁Mr 1.125
. 0.0015707015991210938
▁B 0.0014781951904296875
' 0.0241546630859375
s 0.0006914138793945312
▁Case 0.044921875
: 0.049835205078125
<0x0A> 0.2310791015625
Mr 0.306640625
. 0.0020961761474609375
▁B 0.0015401840209960938
, 1.2392578125
▁diagn 3.353515625
osed 7.641315460205078e-05
▁with 0.01123809814453125
▁advanced 0.95361328125
▁mel 0.0775146484375
an 3.266334533691406e-05
oma 5.5909156799316406e-05
, 0.162353515625
▁exempl 5.12890625
ifies 0.0134429931640625
▁the 0.047210693359375
▁potential 0.6103515625
▁of 2.734375
▁imm 0.44775390625
une 0.0121917724609375
▁check 0.0018444061279296875
point 0.0015573501586914062
▁in 0.0014190673828125
hib 8.344650268554688e-07
itors 0.007080078125
▁to 4.3828125
▁achieve 2.38671875
▁rem 3.587890625
ission 0.001331329345703125
. 1.0751953125
▁With 3.455078125
▁p 2.666015625
emb 0.005706787109375
rol 8.320808410644531e-05
iz 6.663799285888672e-05
um 0.000194549560546875
ab 2.8371810913085938e-05
▁treatment 1.2099609375
, 0.036895751953125
▁his 2.19140625
▁tum 0.58447265625
or 0.34423828125
▁shr 1.9814453125
inks 4.56640625
▁significantly 1.7978515625
, 0.2371826171875
▁leading 3.177734375
▁to 0.0078887939453125
▁increased 5.1328125
▁overall 3.654296875
▁surv 0.04925537109375
ival 0.0002837181091308594
▁and 1.2099609375
▁quality 1.869140625
▁of 0.0039520263671875
▁life 0.0002932548522949219
. 0.03399658203125
<0x0A> 0.290771484375
Con 1.4130859375
clusion 0.007221221923828125
: 0.077880859375
<0x0A> 7.8984375
The 2.15234375
▁adv 1.15625
anc 0.130126953125
ements 1.2636184692382812e-05
▁in 0.039886474609375
▁imm 0.455078125
une 0.05206298828125
▁check 0.0022716522216796875
point 0.0028228759765625
▁in 0.0009551048278808594
hib 1.5497207641601562e-06
itors 0.0126495361328125
▁and 0.01021575927734375
▁adj 0.002719879150390625
uv 0.00023698806762695312
ant 0.00014698505401611328
▁ther 0.006801605224609375
ap 0.0019321441650390625
ies 2.7418136596679688e-06
▁have 0.642578125
▁revolution 1.0947265625
ized 0.0003609657287597656
▁mel 2.158203125
an 1.1682510375976562e-05
oma 4.887580871582031e-05
▁treatment 0.10491943359375
, 0.75732421875
▁offering 0.9375
▁improved 3.333984375
▁surv 0.475341796875
ival 0.0006113052368164062
▁rates 0.038665771484375
▁and 0.169921875
▁the 5.703125
▁potential 0.1383056640625
▁for 0.2181396484375
▁long 0.103759765625
- 0.0011262893676757812
term 0.0095672607421875
▁rem 0.0033168792724609375
ission 0.00649261474609375
. 0.14990234375
▁These 1.0234375
▁treat 0.43701171875
ments 1.2636184692382812e-05
▁have 1.5322265625
▁shown 2.0390625
▁particular 2.31640625
▁effic 2.505859375
acy 2.288818359375e-05
▁in 0.04437255859375
▁patients 0.68408203125
▁with 0.07720947265625
▁advanced 0.031982421875
▁mel 0.59814453125
an 1.5735626220703125e-05
oma 0.0068359375
, 0.50390625
▁while 1.810546875
▁on 2.94140625
going 0.000949859619140625
▁research 0.318603515625
▁expl 2.23046875
ores 0.0014286041259765625
▁their 0.0289154052734375
▁benefits 3.92578125
▁for 2.4140625
▁patients 0.77099609375
▁at 0.41455078125
▁earlier 0.876953125
▁stages 0.013458251953125
. 0.42041015625
▁The 1.810546875
▁case 0.0831298828125
▁of 0.0125274658203125
▁Mr 0.0006432533264160156
. 0.0011463165283203125
▁B 0.0016117095947265625
▁further 4.87109375
▁demonstr 2.275390625
ates 1.4543533325195312e-05
▁the 0.036712646484375
▁prof 5.65625
ound 0.00049591064453125
▁impact 0.0665283203125
▁these 2.23046875
▁ther 1.984375
ap 3.4689903259277344e-05
ies 4.100799560546875e-05
▁can 0.06622314453125
▁have 0.019866943359375
▁on 0.075439453125
▁patients 1.8125
' 0.380615234375
▁lives 0.267822265625
, 1.3271484375
▁insp 3.65625
iring 5.8650970458984375e-05
▁hope 0.07427978515625
▁for 0.43310546875
▁a 1.5986328125
▁br 0.54833984375
ighter 7.271766662597656e-06
▁future 0.0176239013671875
▁in 0.6728515625
▁mel 2.134765625
an 8.702278137207031e-06
oma 3.361701965332031e-05
▁management 1.97265625
. 0.03680419921875
